1. Develop a wearable sensor package to gather data on COVID-19-like signs and symptoms such as elevated body temperature, respiratory parameters, heart rate ,cough and gait. 2. Create algorithms to monitor and track changes to COVID19-like signs and symptoms for developing a better care and isolation strategies for COVID-19 pandemic.

Prospective nationwide cohort study of pregnant women enrolled early in gestation andfollowed for Covid-19 exposure and infection, with follow up of obstetrical outcomes andinfant development through the first year of life.

Background:COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract.Some people who get COVID-19 have only mild symptoms. But for others, infection leads topneumonia, respiratory failure, and, in some cases, death. Researchers want to learn moreabout any effects that may persist after people recover from COVID-19.Objective:To learn about any long-term medical problems that people who have recovered fromCOVID-19 might have, and whether they develop an immune response to SARS-CoV-2 thatprovides protection against reinfection.Eligibility:People age 18 and older who have recovered from documented COVID-19 or were in closecontact with someone who had COVID-19 but did not get the infectionDesign:Participants will be screened over 2 visits. During visit 1, they will answer questionsabout any symptoms they are having and will be tested for SARS-CoV-2 infection which willinvolve a nasal swab sample or other FDA approved test. If the test is negative, theywill proceed to the second visit, which will include:Physical examinationMedical historyMental health interview (which may be recorded if the participant agrees)Chest x-ray (for recovered COVID-19 participants only)Blood and urine testsPregnancy test (if needed)Lung function test (for recovered COVID-19 participants only)6-minute walk test (for recovered COVID-19 participants only)Questionnaires about their general and mental healthLeukapheresis to collect white blood cells (optional).Participants will be put into 1 of 2 groups: the COVID-19 group or the close contactgroup.Participants will have study visits every 6 months for 3 years. They will repeat some ofthe screening tests. Participants in the COVID-19 group may have visits more often ifthey develop symptoms that suggest re-infection with SARS-CoV-2.

This study collects blood samples, medical information, and medical images from patientswho are being treated for cancer and have a positive test for SARS CoV-2, the newcoronavirus that causes the disease called COVID-19. Collecting blood samples, medicalinformation, and medical images may help researchers determine how COVID-19 affects theoutcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Our long-term goal is to protect the health care workforce (HCW) caring forSARS-CoV-2-infected patients, their families, communities, and the general population.Our specific objective is to rapidly establish a prospective cohort to characterize thefactors related to viral transmission and disease severity in a large healthcare system.We addressed this hypothesis by recruiting and longitudinally following 546 HCW and acomparison group of 283 non-HCW within a large academic health system, Rutgers Biomedicaland Health Sciences (RBHS). By intensively following participants over a several yearperiod (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs,blood, and saliva) and questionnaire data at multiple time points, we will uniquelycharacterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and ourlarger academic community.

This is a Phase II interventional study testing whether treatment withhydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19

The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viralpneumopathy that can progress to acute respiratory distress syndrome (ARDS). Thehost-pathogen relationships and the physiopathological mechanisms underlying the clinicalaggravation of COVID-19 patients remain misunderstood. The project aim is to create aprospective cohort of biological samples collected from well characterized COVID-19patients. This project aims first to identify based on these samples an early immunesignature predictive of clinical worsening of COVID-19 patients in order to improve theirmanagement, and secondarily to better understand pathophysiological mechanisms underlyingthe different phases of the disease in order to identify innovative therapeutic targetsand vaccine perspectives.

The purpose of this study is to test whether Fisetin, a senolytic drug, can assist inpreventing an increase in the disease's progression and alleviate complications ofcoronavirus due to an excessive inflammatory reaction.

The COVID-19 crisis began in China in December 2019 and was declared a pandemic by theWorld Health Organisation on March 11th 2020. The pandemic has changed the way thatclinicians interact with and treat patients overnight. Staff within the NHS will be underhigh levels of stress due to the increased needs and worse outcomes of work as they areshielding or self-isolating and may feel helpless and guilty. The psychological impact ofthe pandemic will be prolonged and varied. It is vital that Investigators increaseunderstanding as much as possible to support NHS staff.The aim of this survey is to examine the possible mental health burden on NHS staff as aresult of the COVID-19 pandemic and how these change as the pandemic progresses. Byunderstanding these effects, it will allow researchers to identify recommendations toallow support mechanisms to be put in place for NHS staff, to better manage this andfuture pandemics and similar crises.Investigators are aiming to sample several cohorts of NHS staff including a subset ofstaff who are shielding. Staff will be asked to complete a series of online surveys atmultiple timepoint: on study initiation, 1 month later and then 3 months after thepandemic has ceased in the UK. Additional timepoints may be added depending on the lengthand severity of the pandemic.The main outcomes will be tracking changes in mental health measurements at thepre-defined timepoints. This work will allow Investigators to produce recommendationsabout the increased mental health support that NHS staff will need. If a need isdemonstrated then an interventional research project will be designed and implemented.

Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) isreferred to as COVID-19 convalescent plasma (CCP), and may contain antibodies againstSARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as atherapeutic or prophylactic approach in COVID-19 patients. The goal of this study is tohelp develop a bank of convalescent plasma in California, especially in medicallyunderserved communities particularly affected by the disease. In parallel, CCPadministered to COVID-19 patients will be collected and analyzed to determine whether theantibody profile correlates with clinical outcome. The purpose of this non-therapeuticstudy is to learn more about the CCP antibody profile and the effect it may have intreating COVID-19 infection.